Ventas Inc. (VTR) has reached an all-time high of $87.20 per share, marking a significant milestone for the healthcare REIT with a 30.45% increase over the past year. Despite its strong performance and sustained dividend payments for 28 years, the stock appears overvalued compared to analyst targets. KeyBanc, Goldman Sachs, Cantor Fitzgerald, and Evercore ISI have all recently raised their price targets for Ventas, citing strong growth and operational results.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Ventas stock reaches all-time high at 87.2 USD
Ventas Inc. (VTR) has reached an all-time high of $87.20 per share, marking a significant milestone for the healthcare REIT with a 30.45% increase over the past year. Despite its strong performance and sustained dividend payments for 28 years, the stock appears overvalued compared to analyst targets. KeyBanc, Goldman Sachs, Cantor Fitzgerald, and Evercore ISI have all recently raised their price targets for Ventas, citing strong growth and operational results.